Raymond James & Associates Moleculin Biotech, Inc. Transaction History

Raymond James & Associates

  • $150 Billion
  • Q2 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 08, 2022
SELL
$1.64 - $2.83 $23,247 - $40,115
-14,175 Closed
0 $0
Q3 2021

Nov 02, 2021
SELL
$2.7 - $3.59 $2,189 - $2,911
-811 Reduced 5.41%
14,175 $43,000
Q1 2021

May 14, 2021
BUY
$3.7 - $6.42 $55,448 - $96,210
14,986 New
14,986 $61,000

Others Institutions Holding MBRX

# of Institutions
2
Shares Held
3.35K
Call Options Held
0
Put Options Held
0
View Full List

About Moleculin Biotech, Inc.

MBRX Quotes by TradingView
  • Ticker MBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,606,700
  • Market Cap $78.7M
  • Description
  • Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs....
More about MBRX
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email